Management of lipid abnormalities associated with end-stage renal disease.
The management of lipid abnormalities in patients with end-stage renal disease (ESRD) remains controversial. Large, well-designed studies investigating the effects of dyslipidemia on cardiovascular (CV) morbidity and mortality and the role of cholesterol lowering drugs in reducing mortality in ESRD patients are lacking. While it seems reasonable to suspect that dyslipidemia and its treatment in ESRD patients will affect CV morbidity and mortality similar to that in the general population, recent studies have suggested that this may not be the case. Furthermore, the pharmacokinetics of lipid lowering drugs are altered in patients with ESRD and must be considered when treating this group of patients. This article reviews the major classes of drugs used to treat dyslipidemia, emphasizing their role in patients with ESRD.
Liu
Jia
J
Department of Internal Medicine, Division of Nephrology, University of Virginia Health System, Charlottesville, Virginia 22908, USA.
Kalantarinia
Kambiz
K
Rosner
Mitchell H
MH
D000975:Antioxidants / Q000627:therapeutic use; D050171:Dyslipidemias / Q000150:complications* / Q000628:therapy*; D005231:Fatty Acids, Unsaturated / Q000008:administration & dosage; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000628:therapy; D008019:Life Style; D006435:Renal Dialysis; D014815:Vitamins / Q000627:therapeutic use
D000975:Antioxidants; D005231:Fatty Acids, Unsaturated; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D014815:Vitamins